Journal of Clinical Oncology
Articles in this Issue
H.O.P.E. (Hematology/Oncology Practical Education): A pilot curriculum.
e21007 Background: Patients with hematologic malignancies are living longer than ever before, due to advances in diagnosti...
Impact of genomic subtype on intracranial outcomes in treatment-naive <i>EGFR</i> -mutant NSCLC with osimertinib (IGnITE).
2020 Background: Osimertinib is the standard first-line therapy for EGFR -mutant N...
A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed <i>NPM1</i> -mutated or <i>KMT2A</i> -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).
TPS6600 Background: Optimal treatment for patients (pts) with acute myeloid leukemia (AML) unfit for intensive chemotherap...
Implementing a centralized navigator-led and AI-assisted platform to improve lung cancer screening rates and early detection: A 6-year health system analysis.
109 Background: Despite the known mortality benefits of low-dose computed tomography (LDCT) for lung cancer screening (LCS...
Dissecting metastatic castration-resistant prostate cancer using regulatory network analysis of tumor transcriptomes.
5074 Background: Metastatic castration-resistant prostate cancer (mCRPC) is characterized by profound clinical and biologi...
Advancing health equity in oncology: Virtual collaborative behavioral health engagement and outcomes among Medicaid-insured and BIPOC patients.
1552 Background: Depression and anxiety are common among patients with cancer, yet access to behavioral health care remain...
Study on the correlation between gut microbiota and metabolite, brevifolincarboxylic acid, and liver injury caused by third-generation EGFR-TKIs in lung adenocarcinoma.
e20552 Background: For patients with non-small cell lung cancer (NSCLC) who are treated with third-generation EGFR-TKIs, d...
Comparative safety and efficacy of venetoclax-combination therapies versus obinutuzumab-combination therapies in chronic lymphocytic leukemia: A systematic review and meta-analysis.
e19028 Background: Chronic lymphocytic leukemia (CLL) treatment has changed substantially with targeted therapies that ach...
Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b/2 trial.
4198 Background: In China, gemcitabine (G) and nab-paclitaxel (nP) remain the standard first-line (1L) therapy for patient...
Stage at diagnosis and survival outcomes in esophageal carcinoma: A multicenter real-world study.
e16087 Background: Esophageal carcinoma (EC) is a highly lethal malignancy, with prognosis largely dependent on stage at d...
Evolution of the pulmonary immune microenvironment from premalignant lesions to invasive lung adenocarcinoma: A spatial transcriptomic study.
e20029 Background: Pulmonary adenocarcinoma develops through a multistep process from premalignant epithelial lesions to i...
Phase I dose-escalation results of <sup>177</sup> Lu-NYM032 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).
5049 Background: 177 Lu-NYM032 is a novel prostate-specific membrane antigen (PSMA)-targeted radioconj...
Trend analysis of survival, socioeconomic, and racial disparities in esophageal squamous cell carcinoma.
e16133 Background: Esophageal squamous cell carcinoma (ESCC) remains a lethal malignancy in the US, with historically poor...
Analgesia profile and racial disparity in opioid use among cancer patients hospitalized in a public hospital in the countryside, Brazil.
e13753 Background: Cancer-related pain is highly prevalent across all stages of oncologic disease and is considered one of...
Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).
8014 Background: Transcriptomic analyses of pre-Tx tumor samples from the Phase 3 IMpower133 study identified 4 molecular...
Preliminary safety and efficacy of SYS6010 combined with enlonstobart in patients with recurrent or metastatic esophageal cancer: Results from a phase I/II study.
e16052 Background: SYS6010 is a novel antibody-drug conjugate (ADC), consisting of an anti-epidermal growth factor recepto...
Assessment of ctDNA detection in prostate cancer using a 6-base epigenomics and fragmentomics approach.
e17132 Background: Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide. Early detection...
Racial and ethnic disparities in pancreatic cancer risk assessment using SEER–Medicare claims data.
e16010 Background: Racial and ethnic disparities in pancreatic cancer outcomes may be partially driven by differences in r...
Impact of national health insurance "Ayushman Bharat" scheme of delivering high-quality cancer surgery in resource-constrained settings of low/middle-income countries: Correlation of out-of-pocket expenditure with quality metrics.
e13631 Background: Parameters for high quality cancer surgeries are stringent and have been defined for various organ syst...
Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials.
e20041 Background: Consolidative immunotherapy(IO) after chemoradiotherapy (CRT) is the current standard of care for local...
GDF-15 levels and clinical correlates in head and neck cancer patients: Developing a risk model for cachexia.
6099 Background: Cachexia is a challenging complication of cancer and its treatment, associated with an increased risk of...
Efficacy of primary cardioprotection with perindopril, bisoprolol, and trimetazidine in high-risk patients with breast and gastric cancer receiving anthracycline- and trastuzumab-containing therapy.
12028 Background: Anthracyclines and trastuzumab are the most common antitumor agents associated with a substantial risk o...
Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).
TPS6604 Background: In preclinical evaluations, sequential treatment (tx) with RUX, a Janus kinase inhibitor (JAKi), and I...
Carcinomas of unknown primary treated with molecularly guided therapies and immune checkpoint inhibitors: A subset from the I-PREDICT N-of-1 Precision Oncology study.
3135 Background: Carcinoma of unknown primary (CUP) is a heterogenous group of aggressive malignancies lacking a detectabl...
A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with <i>FGFR2</i> fusion or rearrangement.
TPS4251 Background: Tissue agnostic cancer therapies offer the potential to markedly change the treatment landscape by tar...